These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS. Zhang Z, Mahoney EM, Kolm P, Spertus J, Caro J, Willke R, Weintraub WS. Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935 [Abstract] [Full Text] [Related]
4. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. Krum H, Shi H, Pitt B, McMurray J, Swedberg K, van Veldhuisen DJ, Vincent J, Pocock S, Zannad F, EMPHASIS-HF Study Group. Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945 [Abstract] [Full Text] [Related]
5. Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. Levy AR, Briggs AH, Demers C, O'Brien BJ. Am Heart J; 2001 Sep; 142(3):537-43. PubMed ID: 11526370 [Abstract] [Full Text] [Related]
6. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA. Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801 [Abstract] [Full Text] [Related]
7. Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003. Lamb DA, Eurich DT, McAlister FA, Tsuyuki RT, Semchuk WM, Wilson TW, Blackburn DF. Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):228-35. PubMed ID: 20031842 [Abstract] [Full Text] [Related]
8. Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart Failure With Reduced Ejection Fraction. Dixit NM, Parikh NU, Ziaeian B, Jackson N, Fonarow GC. JACC Heart Fail; 2023 May; 11(5):541-551. PubMed ID: 36892492 [Abstract] [Full Text] [Related]
11. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey. Cohen Solal A, Leurs I, Assyag P, Beauvais F, Clerson P, Contre C, Thebaut JF, Genoun M, French National College of Cardiologists. Arch Cardiovasc Dis; 2012 May; 105(6-7):355-65. PubMed ID: 22800720 [Abstract] [Full Text] [Related]
12. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study. de Pouvourville G, Solesse A, Beillat M. Arch Cardiovasc Dis; 2008 Sep; 101(9):515-21. PubMed ID: 19041835 [Abstract] [Full Text] [Related]
16. Effect of Valsartan on hospitalization: results from Val-HeFT. Carson P, Tognoni G, Cohn JN. J Card Fail; 2003 Jun; 9(3):164-71. PubMed ID: 12815565 [Abstract] [Full Text] [Related]
17. Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costs. Skrepnek GH, Abarca J, Malone DC, Armstrong EP, Shirazi FM, Woosley RL. Ann Pharmacother; 2005 Nov; 39(11):1785-91. PubMed ID: 16219900 [Abstract] [Full Text] [Related]
18. Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: Results from TSOC-HFrEF registry. Chang HY, Wang CC, Wei J, Chang CY, Chuang YC, Huang CL, Chong E, Lin JL, Mar GY, Chan KC, Kuo JY, Wang JH, Chen ZC, Tseng WK, Cherng WJ, Yin WH. J Chin Med Assoc; 2017 Dec; 80(12):750-757. PubMed ID: 29033112 [Abstract] [Full Text] [Related]